| Nome |
# |
|
Apatinib for the treatment of gastric cancer, file e2913fdb-5966-f688-e053-3705fe0a67e0
|
1.197
|
|
Current challenges in HER2-positive breast cancer, file e2913fdb-58d9-f688-e053-3705fe0a67e0
|
664
|
|
Lenvatinib for the treatment of renal cell carcinoma, file e2913fdd-82b6-f688-e053-3705fe0a67e0
|
494
|
|
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper, file e2913fdc-d489-f688-e053-3705fe0a67e0
|
354
|
|
CTLA-4 in Regulatory T Cells for Cancer Immunotherapy, file e2913fde-36ac-f688-e053-3705fe0a67e0
|
339
|
|
Abemaciclib: A CDK4/6 inhibitor for the treatment of HR+/HEeR2- advanced breast cancer, file e2913fdc-d0a0-f688-e053-3705fe0a67e0
|
315
|
|
Broad targeting of angiogenesis for cancer prevention and therapy, file e2913fdb-5a81-f688-e053-3705fe0a67e0
|
306
|
|
Designing a broad-spectrum integrative approach for cancer prevention and treatment, file e2913fdb-6864-f688-e053-3705fe0a67e0
|
232
|
|
PIK3CA mutation in gastric cancer and the role of microsatellite instability status in mutations of exons 9 and 20 of the PIK3CA gene, file e2913fdc-d40a-f688-e053-3705fe0a67e0
|
219
|
|
Cell-free DNA integrity for the monitoring of breast cancer: Future perspectives?, file e2913fdc-3bf3-f688-e053-3705fe0a67e0
|
217
|
|
Cyclin dependent kinase 4 and 6 inhibitors as novel therapeutic agents for targeted treatment of malignant mesothelioma, file e2913fdb-9a7c-f688-e053-3705fe0a67e0
|
216
|
|
Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer, file e2913fdc-615d-f688-e053-3705fe0a67e0
|
210
|
|
Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit, file e2913fdc-d416-f688-e053-3705fe0a67e0
|
197
|
|
Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility, file e2913fdb-5f2b-f688-e053-3705fe0a67e0
|
196
|
|
Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study., file e2913fdc-6eb3-f688-e053-3705fe0a67e0
|
189
|
|
Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer, file e2913fdc-d259-f688-e053-3705fe0a67e0
|
181
|
|
Enteric-coated and highly standardized cranberry extract reduces antibiotic and nonsteroidal anti-inflammatory drug use for urinary tract infections during radiotherapy for prostate carcinoma, file e2913fdb-5c57-f688-e053-3705fe0a67e0
|
177
|
|
Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma, file e2913fdc-f266-f688-e053-3705fe0a67e0
|
169
|
|
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial, file e2913fdb-6a56-f688-e053-3705fe0a67e0
|
166
|
|
Circulating tumor cells correlate with patterns of recurrence in patients with hormone-sensitive prostate cancer, file e2913fdb-fe1c-f688-e053-3705fe0a67e0
|
164
|
|
Bevacizumab in small cell lung cancer, file e2913fdc-053f-f688-e053-3705fe0a67e0
|
162
|
|
Isolated testicular metastasis from prostate cancer, file e2913fdb-fe0d-f688-e053-3705fe0a67e0
|
160
|
|
Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter study, file e2913fdb-71a4-f688-e053-3705fe0a67e0
|
157
|
|
Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer, file e2913fda-0578-f688-e053-3705fe0a67e0
|
154
|
|
Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts, file e2913fdc-d25d-f688-e053-3705fe0a67e0
|
154
|
|
Hypoxia-related biological markers as predictors of epirubicinbased treatment responsiveness and resistance in locally advanced breast cancer, file e2913fdc-05b5-f688-e053-3705fe0a67e0
|
153
|
|
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells, file e2913fdc-d0a7-f688-e053-3705fe0a67e0
|
145
|
|
Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study, file e2913fdc-a29f-f688-e053-3705fe0a67e0
|
132
|
|
Would the combination of everolimus with endocrine-therapy help in FGFR2 positive serous endometrial cancer?, file e2913fdb-6f42-f688-e053-3705fe0a67e0
|
124
|
|
Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition, file e2913fdb-6636-f688-e053-3705fe0a67e0
|
118
|
|
Role of targeted agents in neuroendocrine tumors: Results from a meta-analysis, file e2913fdb-5fdc-f688-e053-3705fe0a67e0
|
116
|
|
Characterization of MTAP gene expression in breast cancer patients and cell lines, file e2913fdb-61f2-f688-e053-3705fe0a67e0
|
115
|
|
Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration, file e2913fdb-5c18-f688-e053-3705fe0a67e0
|
108
|
|
PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy, file e2913fdc-181e-f688-e053-3705fe0a67e0
|
105
|
|
Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies, file e2913fdc-2c15-f688-e053-3705fe0a67e0
|
100
|
|
Triple Negative Breast Cancers Have a Reduced Expression of DNA Repair Genes, file e2913fda-008e-f688-e053-3705fe0a67e0
|
99
|
|
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study, file e2913fdc-b384-f688-e053-3705fe0a67e0
|
97
|
|
The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials, file e2913fdf-155a-f688-e053-3705fe0a67e0
|
90
|
|
BRAF Signaling Inhibition in Glioblastoma: Which Clinical Perspectives?, file e2913fdf-76bc-f688-e053-3705fe0a67e0
|
86
|
|
Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature, file e2913fde-2543-f688-e053-3705fe0a67e0
|
79
|
|
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study, file e2913fde-8323-f688-e053-3705fe0a67e0
|
78
|
|
Early changes of the standardized uptake values (SUVmax) predict the efficacy of everolimus-exemestane in patients with hormone receptor-positive metastatic breast cancer, file e2913fde-36a9-f688-e053-3705fe0a67e0
|
65
|
|
Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer, file e2913fde-7f5a-f688-e053-3705fe0a67e0
|
65
|
|
Need for randomized clinical trials testing targeted therapies in malignant pleural mesothelioma, file e2913fdb-d791-f688-e053-3705fe0a67e0
|
57
|
|
Management of the axilla in breast cancer: outcome analysis in a series of ductal versus lobular invasive cancers, file e2913fdf-01ac-f688-e053-3705fe0a67e0
|
56
|
|
Cytokine Profiles as Potential Prognostic and Therapeutic Markers in SARS-CoV-2-Induced ARDS, file e2913fdf-bbba-f688-e053-3705fe0a67e0
|
53
|
|
P53 antibodies as a diagnostic marker for cancer: A meta-analysis, file e2913fdf-76bf-f688-e053-3705fe0a67e0
|
50
|
|
Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis, file e2913fdc-2c19-f688-e053-3705fe0a67e0
|
49
|
|
Low-Dose Oral Ethinylestradiol With Concomitant Low-Dose Acetylsalicylic Acid for Advanced Castrate-Resistant Prostate Cancer, file e2913fdb-95f1-f688-e053-3705fe0a67e0
|
42
|
|
Colorectal cancer-screening program improves both short- and long-term outcomes: a single-center experience in Trieste, file e2913fdf-1dd8-f688-e053-3705fe0a67e0
|
42
|
|
Analysis of PD-L1 and CD3 Expression in Glioblastoma Patients and Correlation with Outcome: A Single Center Report, file 82df134a-3361-45aa-a354-1b1e0bde9d6d
|
38
|
|
Impact of psychosocial, behavioral and lifestyle factors on subjective cognitive complaints and perceived quality of life in a large cohort of Italian
breast cancer patients, file 1cdbdab8-66cf-4e34-86d8-9ae5392fe8fe
|
34
|
|
Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2- Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study, file d4c97161-fb64-4738-a23a-9fd9bc7b5496
|
34
|
|
Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial, file e2913fde-36a7-f688-e053-3705fe0a67e0
|
34
|
|
PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy, file e2913fde-bc16-f688-e053-3705fe0a67e0
|
33
|
|
Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: The OnCovid Inflammatory Score, file e2913fde-c11d-f688-e053-3705fe0a67e0
|
33
|
|
A Case–Control Study by ddPCR of ALU 260/111 and LINE-1 266/97 Copy Number Ratio in Circulating Cell-Free DNA in Plasma Revealed LINE-1 266/97 as a Potential Biomarker for Early Breast Cancer Detection, file 2709e941-8cc1-40fd-9924-a3e3be84594b
|
32
|
|
Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-Positive breast cancer patients treated with chemotherapy and HER2-Targeted agents in the CherLOB trial, file e2913fdf-457b-f688-e053-3705fe0a67e0
|
32
|
|
Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trials, file e2913fdb-5fde-f688-e053-3705fe0a67e0
|
31
|
|
Circulating cell-free nucleic acids as prognostic and therapy predictive tools for metastatic castrate-resistant prostate cancer, file e2913fdd-5095-f688-e053-3705fe0a67e0
|
29
|
|
The Predictive and Prognostic Role of RAS-RAF-MEK-ERK Pathway Alterations in Breast Cancer: Revision of the Literature and Comparison with the Analysis of Cancer Genomic Datasets, file 74eb81ad-b44e-442d-a9c3-0123e5b39733
|
27
|
|
Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation, file b5314b26-6389-4e00-8cce-f0c8e4b2df24
|
27
|
|
Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis, file e2913fde-7b47-f688-e053-3705fe0a67e0
|
25
|
|
Treating advanced breast cancer with metronomic chemotherapy: What is known, what is new and what is the future?, file a03bea5c-644b-451a-ab12-a1b18a5bfac7
|
24
|
|
Role of the IGF-1 Axis in Overcoming Resistance in Breast Cancer, file e2913fde-4d58-f688-e053-3705fe0a67e0
|
24
|
|
Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study, file e2913fde-3c14-f688-e053-3705fe0a67e0
|
23
|
|
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial, file e2913fde-4d52-f688-e053-3705fe0a67e0
|
23
|
|
Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer, file 37828fe0-15d8-498f-be8e-99dde4d17714
|
22
|
|
Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation, file 5edc65f5-24f7-480b-850a-b89025e610b5
|
22
|
|
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: Primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET), file e2913fdf-155b-f688-e053-3705fe0a67e0
|
22
|
|
Cytokine Profiles as Potential Prognostic and Therapeutic Markers in SARS-CoV-2-Induced ARDS, file e2913fdf-bda0-f688-e053-3705fe0a67e0
|
22
|
|
Anthracyclines strike back: Rediscovering non‐pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer, file e2913fdf-76c4-f688-e053-3705fe0a67e0
|
21
|
|
Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration, file e2913fdb-7e29-f688-e053-3705fe0a67e0
|
19
|
|
Mutant p53 as an antigen in cancer immunotherapy, file e2913fde-7f5c-f688-e053-3705fe0a67e0
|
19
|
|
Next-Generation Sequencing and Triple-Negative Breast Cancer: Insights and Applications, file 9592e9f4-848c-4d83-b144-3c7325a9846c
|
18
|
|
Epithelioid Mesothelioma Patients with Very Long Survival Display Defects in DNA Repair, file c17be2fd-de8c-4a6c-bfb4-c7d0a69b59eb
|
18
|
|
Immune-related pan-cancer gene expression signatures of patient survival revealed by NanoString-based analyses, file cab21b97-0562-49e6-98ff-ed44a739ea5e
|
18
|
|
Oncological care organisation during COVID-19 outbreak, file e2913fde-6615-f688-e053-3705fe0a67e0
|
18
|
|
Expected medium- And long-term impact of the COVID-19 outbreak in oncology, file e2913fde-6617-f688-e053-3705fe0a67e0
|
17
|
|
Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice, file ae451a81-378a-48a9-8701-fcb6b333a0ee
|
16
|
|
The G-protein-coupled receptor CLR is upregulated in an autocrine loop with adrenomedullin in clear cell renal cell carcinoma and associated with poor prognosis, file e2913fda-0089-f688-e053-3705fe0a67e0
|
16
|
|
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial, file e2913fde-2a59-f688-e053-3705fe0a67e0
|
16
|
|
Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: A retrospective exploratory analysis of the BALLET study, file e2913fde-2bf1-f688-e053-3705fe0a67e0
|
16
|
|
EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience, file e2913fde-34fc-f688-e053-3705fe0a67e0
|
16
|
|
Predictive and Prognostic Value of Non-Coding RNA in Breast Cancer, file 46250e37-ab51-4473-a084-f1b0607fe7d0
|
15
|
|
Updates on the CDK4/6 inhibitory strategy and combinations in breast cancer, file 65498b7f-6545-4b8e-bb41-93b6e909eebb
|
15
|
|
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial, file e2913fdb-7749-f688-e053-3705fe0a67e0
|
15
|
|
Lenvatinib for the treatment of renal cell carcinoma, file e2913fdd-555e-f688-e053-3705fe0a67e0
|
15
|
|
COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry, file e2913fdf-85e4-f688-e053-3705fe0a67e0
|
15
|
|
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells, file 66e0dd45-7a3f-45f8-86e3-34b88af6390b
|
14
|
|
BRCA Mutation Status in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Pivotal Role for Treatment Decision-Making, file 0cb99f9c-c7e4-46ec-b699-7ff650e15603
|
13
|
|
Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort Study, file e2913fde-42b8-f688-e053-3705fe0a67e0
|
13
|
|
Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study, file e2913fde-7f57-f688-e053-3705fe0a67e0
|
13
|
|
Combining inhibition of immune checkpoints and PARP: rationale and perspectives in cancer treatment, file 8e0c86d2-2da3-4557-b69d-b8b0293c1603
|
12
|
|
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study, file e2913fde-2545-f688-e053-3705fe0a67e0
|
12
|
|
ΔKi67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatment, file e2913fde-4d54-f688-e053-3705fe0a67e0
|
12
|
|
Computational reactive-diffusive modeling for stratification and prognosis determination of patients with breast cancer receiving Olaparib, file ec59ed15-0f27-4103-a0d4-11c30f0bc1b2
|
11
|
|
Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2- Breast Cancer Based on a Window of Opportunity Study, file ba166a05-c67b-4cfb-8337-deff0b217d0d
|
10
|
|
Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer, file e2913fde-4d50-f688-e053-3705fe0a67e0
|
10
|
|
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET), file e2913fdf-b866-f688-e053-3705fe0a67e0
|
10
|
| Totale |
10.237 |